Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
6 "ERCC1"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial
Min Hwan Kim, Xianglan Zhang, Minkyu Jung, Inkyung Jung, Hyung Soon Park, Seung-Hoon Beom, Hyo Song Kim, Sun Young Rha, Hyunki Kim, Yoon Young Choi, Taeil Son, Hyoung-Il Kim, Jae-Ho Cheong, Woo Jin Hyung, Sung Hoon Noh, Hyun Cheol Chung
Cancer Res Treat. 2019;51(2):819-831.   Published online September 27, 2018
DOI: https://doi.org/10.4143/crt.2018.331
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
Identification of biomarkers to predict recurrence risk is essential to improve adjuvant treatment strategies in stage II/III gastric cancer patients. This study evaluated biomarkers for predicting survival after surgical resection.
Materials and Methods
This post-hoc analysis evaluated patients from the CLASSIC trial who underwent D2 gastrectomy with or without adjuvant chemotherapy (capecitabine plus oxaliplatin) at the Yonsei Cancer Center. Tumor expressions of thymidylate synthase (TS), excision repair cross-complementation group 1 (ERCC1), and programmed death-ligand 1 (PD-L1) were evaluated by immunohistochemical (IHC) staining to determine their predictive values.
Results
Among 139 patients, IHC analysis revealed high tumor expression of TS (n=22, 15.8%), ERCC1 (n=23, 16.5%), and PD-L1 (n=42, 30.2%) in the subset of patients. Among all patients, high TS expression tended to predict poor disease-free survival (DFS; hazard ratio [HR], 1.80; p=0.053), whereas PD-L1 positivity was associated with favorable DFS (HR, 0.33; p=0.001) and overall survival (OS; HR, 0.38; p=0.009) in multivariate Cox analysis. In the subgroup analysis, poor DFS was independently predicted by high TS expression (HR, 2.51; p=0.022) in the adjuvant chemotherapy subgroup (n=66). High PD-L1 expression was associated with favorable DFS (HR, 0.25; p=0.011) and OS (HR, 0.22; p=0.015) only in the surgery-alone subgroup (n=73). The prognostic impact of high ERCC1 expression was not significant in the multivariate Cox analysis.
Conclusion
This study shows that high TS expression is a predictive factor for worse outcomes on capecitabine plus oxaliplatin adjuvant chemotherapy, whereas PD-L1 expression is a favorable prognostic factor in locally advanced gastric cancer patients.

Citations

Citations to this article as recorded by  
  • Utility of TMPRSS4 as a Prognostic Biomarker and Potential Therapeutic Target in Patients with Gastric Cancer
    Hirofumi Tazawa, Takahisa Suzuki, Akihisa Saito, Akira Ishikawa, Toshiaki Komo, Haruki Sada, Norimitsu Shimada, Naoto Hadano, Takashi Onoe, Takeshi Sudo, Yosuke Shimizu, Kazuya Kuraoka, Hirotaka Tashiro
    Journal of Gastrointestinal Surgery.2022; 26(2): 305.     CrossRef
  • Scoring systems for PD-L1 expression and their prognostic impact in patients with resectable gastric cancer
    Marina Alessandra Pereira, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Renan Ribeiro, Leonardo Cardili, Bruno Zilberstein, Ivan Cecconello, Ulysses Ribeiro, Evandro Sobroza de Mello, Tiago Biachi de Castria
    Virchows Archiv.2021; 478(6): 1039.     CrossRef
  • Epstein–Barr Virus Positive Gastric Cancer: A Distinct Subtype Candidate for Immunotherapy
    Marina Alessandra Pereira, Daniel Amadeus Molon Batista, Marcus Fernando Kodama Pertille Ramos, Leonardo Cardili, Renan Ribeiro e Ribeiro, Andre Roncon Dias, Bruno Zilberstein, Ulysses Ribeiro Jr, Ivan Cecconello, Venâncio Avancini Ferreira Alves, Evandro
    Journal of Surgical Research.2021; 261: 130.     CrossRef
  • Cytotoxic T‐lymphocyte‐associated protein 4 in gastric cancer: Prognosis and association with PD‐L1 expression
    Marina Alessandra Pereira, Tiago Biachi de Castria, Marcus Fernando Kodama Pertille Ramos, André Roncon Dias, Leonardo Cardili, Rafael Dyer Rodrigues de Moraes, Bruno Zilberstein, Sergio Carlos Nahas, Ulysses Ribeiro, Evandro Sobroza de Mello
    Journal of Surgical Oncology.2021; 124(7): 1040.     CrossRef
  • Remnant gastric cancer: a neglected group with high potential for immunotherapy
    Marcus Fernando Kodama Pertille Ramos, Marina Alessandra Pereira, Tiago Biachi de Castria, Renan Ribeiro e Ribeiro, Leonardo Cardili, Evandro Sobroza de Mello, Bruno Zilberstein, Ulysses Ribeiro-Júnior, Ivan Cecconello
    Journal of Cancer Research and Clinical Oncology.2020; 146(12): 3373.     CrossRef
  • Molecular Bases of Mechanisms Accounting for Drug Resistance in Gastric Adenocarcinoma
    Jose J. G. Marin, Laura Perez-Silva, Rocio I. R. Macias, Maitane Asensio, Ana Peleteiro-Vigil, Anabel Sanchez-Martin, Candela Cives-Losada, Paula Sanchon-Sanchez, Beatriz Sanchez De Blas, Elisa Herraez, Oscar Briz, Elisa Lozano
    Cancers.2020; 12(8): 2116.     CrossRef
  • Clinical Significance of CLDN18.2 Expression in Metastatic Diffuse-Type Gastric Cancer
    Seo Ree Kim, Kabsoo Shin, Jae Myung Park, Han Hong Lee, Kyo Yong Song, Sung Hak Lee, Bohyun Kim, Sang-Yeob Kim, Junyoung Seo, Jeong-Oh Kim, Sang-Young Roh, In-Ho Kim
    Journal of Gastric Cancer.2020; 20(4): 408.     CrossRef
  • Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis
    van den Ende, ter Veer, Mali, van Berge Henegouwen, Hulshof, van Oijen, van Laarhoven
    Cancers.2019; 11(4): 530.     CrossRef
  • 11,754 View
  • 318 Download
  • 9 Web of Science
  • 8 Crossref
Close layer
ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer
Ji-Youn Han, Geon Kook Lee, Kun Young Lim, Young Ju Lee, Byung Ho Nam, Jin Soo Lee
Cancer Res Treat. 2017;49(3):678-687.   Published online October 11, 2016
DOI: https://doi.org/10.4143/crt.2016.365
AbstractAbstract PDFSupplementary MaterialPubReaderePub
Purpose
We evaluated the clinical utility of excision repair cross-complementation group 1 (ERCC1) expression as a predictive biomarker for platinum-based chemotherapy in advanced non-small cell lung cancer (NSCLC).
Materials and Methods
Eligible patients were randomly assigned to the GP (gemcitabine 1,250 mg/m2 on days 1 and 8, and cisplatin 75 mg/m2 on day 1 every 3 weeks) or IP (irinotecan 65 mg/m2 and cisplatin 30 mg/m2 on days 1 and 8 every 3 weeks) arm. The primary goal of this study was to compare the response rate (RR) of the GP and IP arms according to the ERCC1 expression level.
Results
A total of 279 patients were randomly assigned to the GP (n=139) and IP (n=140) arms, among which 63% were ERCC1-positive and 268 patients were assessable for the RR. The GP and IP arms did not differ significantly with respect to the RR (29.8% vs. 27.0%, respectively; p=0.082), median progression-free survival (PFS; 4.5 months vs. 3.9 months, respectively; p=0.117), and overall survival (OS; 16.5 months vs. 16.7 months, respectively; p=0.313). When comparing the efficacy between the ERCC1-positive and ERCC1-negative groups, there was no significant difference in the RR (GP, 28.2% vs. 32.6%, respectively, p=0.509; IP, 30.2% vs. 21.6%, respectively, p=0.536), median PFS (GP, 4.6 months vs. 5.0 months, respectively, p=0.506; IP, 3.9 months vs. 3.7 months, respectively, p=0.748), or median OS (GP, 18.6 months vs. 11.9 months, respectively, p=0.070; IP, 17.5 months vs. 14.0 months, respectively, p=0.821).
Conclusion
Immunohistochemical analysis of the ERCC1 expression level did not differentiate the efficacy of platinum-based chemotherapy in advanced NSCLC.

Citations

Citations to this article as recorded by  
  • Meta‐Analysis of ERCC1 Protein Expression and Platinum Chemosensitivity in Non‐Small‐Cell Lung Cancer
    Guoping Li, Dan Cheng, Jamal A. Mahajna
    Evidence-Based Complementary and Alternative Medicine.2020;[Epub]     CrossRef
  • The role of ERCC1 and AFP gene polymorphism in hepatocellular carcinoma
    Yu-Liang Huang, Jun-Rong Wu, Min Fang, Hui-Liu Zhao, Zhi-Min Liu, Jian Ye, Ling-Sha Huang, Bo Zhu
    Medicine.2019; 98(14): e15090.     CrossRef
  • 10,095 View
  • 196 Download
  • 5 Web of Science
  • 2 Crossref
Close layer
Combination of TRAP1 and ERCC1 Expression Predicts Clinical Outcomes in Metastatic Colorectal Cancer Treated with Oxaliplatin/5-Fluorouracil
Jae Joon Han, Sun Kyung Baek, Jae Jin Lee, Gou Young Kim, Si-Young Kim, Suk-Hwan Lee
Cancer Res Treat. 2014;46(1):55-64.   Published online January 15, 2014
DOI: https://doi.org/10.4143/crt.2014.46.1.55
AbstractAbstract PDFPubReaderePub
PURPOSE
The novel heat shock protein tumor necrosis factor receptor-associated protein 1 (TRAP1) is associated with multidrug resistance in colorectal cancer (CRC) cells in vitro. Excision repair cross-complementation group 1 (ERCC1) expression levels in tumor tissues also predict clinical outcomes in metastatic CRC patients receiving combination oxaliplatin and 5-fluorouracil treatment. We investigated whether TRAP1 and ERCC1 protein expression by immunohistochemistry predict clinical outcomes in CRC patients.
MATERIALS AND METHODS
The study population consisted of 56 patients with metastatic CRC who received first-line oxaliplatin/5-fluorouracil therapy. Clinical response and overall survival (OS) by levels of the markers TRAP1 and ERCC1 were evaluated.
RESULTS
The rates of TRAP1 and ERCC1 expression were 21% and 52%, respectively. Patients negative for ERCC1 expression showed a tendency to respond to chemotherapy (p=0.066). Median OS was significantly longer in patients negative for TRAP1 than those positive for TRAP1 (p=0.023). Patients negative for ERCC1 expression also had a better OS than those positive for ERCC1 (p=0.021). The median OS was 30.9 months for patients negative for TRAP1 and ERCC1 compared to 13.2 months for those positive for TRAP1 and/or positive for ERCC1 expression (p=0.006). The combination of TRAP1 and ERCC1 expression was significantly associated with the response to chemotherapy (p=0.046) and independently predicted median OS in multivariate analysis (hazard ratio, 2.98; 95% confidence interval, 1.18 to 7.49).
CONCLUSION
The present study demonstrates that the combination of TRAP1 and ERCC1 expression predicts the survival of metastatic CRC patients who were treated with oxaliplatin/5-fluorouracil.

Citations

Citations to this article as recorded by  
  • Mitochondria: a crucial factor in the progression and drug resistance of colorectal cancer
    Ying Zhao, Xiaomin Guo, Li Zhang, Dongwei Wang, Yan Li
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • New insights into molecular chaperone TRAP1 as a feasible target for future cancer treatments
    Xiao-Tong Li, Ying-Shuang Li, Zhao-Yu Shi, Xiu-Li Guo
    Life Sciences.2020; 254: 117737.     CrossRef
  • Gene Copy Number and Post-Transductional Mechanisms Regulate TRAP1 Expression in Human Colorectal Carcinomas
    Michele Pietrafesa, Francesca Maddalena, Luciana Possidente, Valentina Condelli, Pietro Zoppoli, Valeria Li Bergolis, Maria Grazia Rodriquenz, Michele Aieta, Giulia Vita, Franca Esposito, Matteo Landriscina
    International Journal of Molecular Sciences.2019; 21(1): 145.     CrossRef
  • HSPA1A, HSPA1L and TRAP1 heat shock genes may be associated with prognosis in ovarian epithelial cancer
    Warne De Andrade, Let�cia Braga, Nikole Gon�ales, Luciana Silva, Agnaldo Da Silva Filho
    Oncology Letters.2019;[Epub]     CrossRef
  • Trps1 is associated with the multidrug resistance of lung cancer cell by regulating MGMT gene expression
    Hongxiang Liu, Yi Liao, Meng Tang, Tao Wu, Deli Tan, Shixin Zhang, Haidong Wang
    Cancer Medicine.2018; 7(5): 1921.     CrossRef
  • Clinical importance of DNA repair in sporadic colorectal cancer
    Gustavo A. Laporte, Natalia M. Leguisamo, Antonio N. Kalil, Jenifer Saffi
    Critical Reviews in Oncology/Hematology.2018; 126: 168.     CrossRef
  • Expression of DDB2 Protein in the Initiation, Progression, and Prognosis of Colorectal Cancer
    Huaiwei Yang, Jingwei Liu, Jingjing Jing, Zeyang Wang, Yi Li, Kaihua Gou, Xue Feng, Yuan Yuan, Chengzhong Xing
    Digestive Diseases and Sciences.2018; 63(11): 2959.     CrossRef
  • Thymidylate synthase expression in primary colorectal cancer as a predictive marker for the response to 5‑fluorouracil‑ and oxaliplatin‑based preoperative chemotherapy for liver metastases
    Hiroshi Takeyama, Tomoko Wakasa, Keisuke Inoue, Kotaro Kitani, Masanori Tsujie, Takafumi Ogawa, Masao Yukawa, Yoshio Ohta, Masatoshi Inoue
    Molecular and Clinical Oncology.2018;[Epub]     CrossRef
  • Clinicopathologic significance of TRAP1 expression in colorectal cancer: a large scale study of human colorectal adenocarcinoma tissues
    Min Gyoung Pak, Hyong Jong Koh, Mee Sook Roh
    Diagnostic Pathology.2017;[Epub]     CrossRef
  • TRAP1: a viable therapeutic target for future cancer treatments?
    Giacomo Lettini, Francesca Maddalena, Lorenza Sisinni, Valentina Condelli, Danilo Swann Matassa, Maria Paola Costi, Daniele Simoni, Franca Esposito, Matteo Landriscina
    Expert Opinion on Therapeutic Targets.2017; 21(8): 805.     CrossRef
  • TRAP1 protein signature predicts outcome in human metastatic colorectal carcinoma
    Francesca Maddalena, Vittorio Simeon, Giulia Vita, Annamaria Bochicchio, Luciana Possidente, Lorenza Sisinni, Giacomo Lettini, Valentina Condelli, Danilo Swann Matassa, Valeria Li Bergolis, Alberto Fersini, Sante Romito, Michele Aieta, Antonio Ambrosi, Fr
    Oncotarget.2017; 8(13): 21229.     CrossRef
  • Nucleotide Excision Repair and Response and Survival to Chemotherapy in Colorectal Cancer Patients
    Elisabeth J Kap, Odilia Popanda, Jenny Chang-Claude
    Pharmacogenomics.2016; 17(7): 755.     CrossRef
  • TRAP1 regulates cell cycle and apoptosis in thyroid carcinoma cells
    Giuseppe Palladino, Tiziana Notarangelo, Giuseppe Pannone, Annamaria Piscazzi, Olga Lamacchia, Lorenza Sisinni, Girolamo Spagnoletti, Paolo Toti, Angela Santoro, Giovanni Storto, Pantaleo Bufo, Mauro Cignarelli, Franca Esposito, Matteo Landriscina
    Endocrine-Related Cancer.2016; 23(9): 699.     CrossRef
  • TRAP1 regulates stemness through Wnt/β-catenin pathway in human colorectal carcinoma
    Giacomo Lettini, Lorenza Sisinni, Valentina Condelli, Danilo Swann Matassa, Vittorio Simeon, Francesca Maddalena, Marica Gemei, Elvira Lopes, Giulia Vita, Luigi Del Vecchio, Franca Esposito, Matteo Landriscina
    Cell Death & Differentiation.2016; 23(11): 1792.     CrossRef
  • TRAP1 downregulation in human ovarian cancer enhances invasion and epithelial–mesenchymal transition
    Maria R Amoroso, Danilo S Matassa, Ilenia Agliarulo, Rosario Avolio, Haonan Lu, Lorenza Sisinni, Giacomo Lettini, Hani Gabra, Matteo Landriscina, Franca Esposito
    Cell Death & Disease.2016; 7(12): e2522.     CrossRef
  • A prognostic analysis of 895 cases of stage III colon cancer in different colon subsites
    Yan Zhang, Junli Ma, Sai Zhang, Ganlu Deng, Xiaoling Wu, Jingxuan He, Haiping Pei, Hong Shen, Shan Zeng
    International Journal of Colorectal Disease.2015; 30(9): 1173.     CrossRef
  • TRAP1 revisited: Novel localizations and functions of a ‘next-generation’ biomarker (Review)
    MARIA ROSARIA AMOROSO, DANILO SWANN MATASSA, LORENZA SISINNI, GIACOMO LETTINI, MATTEO LANDRISCINA, FRANCA ESPOSITO
    International Journal of Oncology.2014; 45(3): 969.     CrossRef
  • 12,332 View
  • 104 Download
  • 20 Web of Science
  • 17 Crossref
Close layer
ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma
Kyun Woo Park, Eun-Seon Jung, Dong-Gu Kim, Young-Kyung Yoo, Tae-Ho Hong, In Seok Lee, Yoon Ho Koh, Ji-Hoon Kim, Myung Ah Lee
Cancer Res Treat. 2013;45(1):63-69.   Published online March 31, 2013
DOI: https://doi.org/10.4143/crt.2013.45.1.63
AbstractAbstract PDFPubReaderePub
PURPOSE
There are three types of bile duct cancer, intrahepatic cholangiocarcinoma (ICC), hilar cholangiocarcinoma (HC), and extrahepatic cholangiocarcinoma (EHC). Despite different clinical presentation, the same protocol has been used in treatment of patients with these cancers. We analyzed clinicopathologic findings and protein expression in order to investigate the difference and the specific prognostic factors among these three types of cancers.
MATERIALS AND METHODS
We conducted a retrospective review of 104 patients diagnosed with bile duct cancer at Seoul St. Mary's Hospital between January 1994 and May 2004. We performed immunohistochemical staining for p53, cyclin D1, thymidine phosphorylase, survivin, and excision repair cross-complementing group 1 (ERCC1).
RESULTS
Of the 104 patients, EHC was most common (44.2%). In pathologic findings, perineural invasion was significantly less common in ICC. Overall survival was similar among the three types of cancer. Lymph node invasion, lymphatic, and venous invasion showed a significant association with survival outcome in ICC, however, the differentiation of histologic grade had prognostic significance in HC and EHC. No difference in protein expression was observed among these types of cancer, however, ERCC1 showed a significant association with survival outcome in HC and EHC, not in ICC.
CONCLUSION
Based on our data, ICC showed different characteristics and prognostic factors, separate from the other two types of bile duct cancer. Conduct of further studies with a large sample size is required in order to confirm these data.

Citations

Citations to this article as recorded by  
  • Systematic Review of Preoperative Prognostic Biomarkers in Perihilar Cholangiocarcinoma
    Rishaan Pawaskar, Kevin Zhang Huang, Helen Pham, Adnan Nagrial, Mark Wong, Siobhan O’Neill, Henry Pleass, Lawrence Yuen, Vincent W. T. Lam, Arthur Richardson, Tony Pang, Christopher B. Nahm
    Cancers.2024; 16(4): 698.     CrossRef
  • Combined Serum ALBUMIN with Neutrophil-to-Lymphocyte Ratio Predicts the Prognosis of Biliary Tract Cancer after Curative Resection
    Tai-Jan Chiu, Yueh-Wei Liu, Chee-Chien Yong, Shih-Min Yin, Cheng-His Yeh, Yen-Yang Chen
    Cancers.2023; 15(22): 5474.     CrossRef
  • Immunotherapy for Cholangiocarcinoma: a 2021 Update
    Nikolaos Charalampakis, Georgios Papageorgiou, Sergios Tsakatikas, Rodanthi Fioretzaki, Christo Kole, Stylianos Kykalos, Maria Tolia, Dimitrios Schizas
    Immunotherapy.2021; 13(13): 1113.     CrossRef
  • Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients
    Andrea Ruzzenente, Matteo Fassan, Simone Conci, Michele Simbolo, Rita T. Lawlor, Corrado Pedrazzani, Paola Capelli, Mirko D’Onofrio, Calogero Iacono, Aldo Scarpa, Alfredo Guglielmi
    Annals of Surgical Oncology.2016; 23(5): 1699.     CrossRef
  • Intracellular autocrine VEGF signaling promotes EBDC cell proliferation, which can be inhibited by Apatinib
    Sui Peng, Yanyan Zhang, Hong Peng, Zunfu Ke, Lixia Xu, Tianhong Su, Allan Tsung, Samer Tohme, Hai Huang, Qiuyang Zhang, Riccardo Lencioni, Zhirong Zeng, Baogang Peng, Minhu Chen, Ming Kuang
    Cancer Letters.2016; 373(2): 193.     CrossRef
  • Prognostic Significance of the Histologic Response of Perihilar Cholangiocarcinoma to Preoperative Neoadjuvant Chemoradiation in Liver Explants
    Heidi D. Lehrke, Julie K. Heimbach, Tsung-Teh Wu, Sarah M. Jenkins, Gregory J. Gores, Charles B. Rosen, Taofic Mounajjed
    American Journal of Surgical Pathology.2016; 40(4): 510.     CrossRef
  • Predictive and prognostic values of ERCC1 and XRCC1 in biliary tract cancers
    Muhtashim Mian, Mairéad G McNamara, Mark Doherty, David Hedley, Jennifer J Knox, Stefano Serra
    Journal of Clinical Pathology.2016; 69(8): 695.     CrossRef
  • Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma
    Hong Peng, Qiuyang Zhang, Jiali Li, Ning Zhang, Yunpeng Hua, Lixia Xu, Yubin Deng, Jiaming Lai, Zhenwei Peng, Baogang Peng, Minhu Chen, Sui Peng, Ming Kuang
    Oncotarget.2016; 7(13): 17220.     CrossRef
  • Correlation between metastatic lymph node ratio and prognosis in patients with extrahepatic cholangiocarcinoma
    Jian-Wei Zhang
    World Journal of Gastroenterology.2015; 21(14): 4255.     CrossRef
  • 12,333 View
  • 49 Download
  • 9 Crossref
Close layer
Predictive Value of the ERCC1 Expression for Treatment Response and Survival in Advanced Gastric Cancer Patients Receiving Cisplatin-based First-line Chemotherapy
Jina Yun, Kyoung-Mee Kim, Seung Tae Kim, Jung-Hoon Kim, Jung A Kim, Jee Hyun Kong, Soo Hyeon Lee, Young-Woong Won, Jong-Mu Sun, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Cancer Res Treat. 2010;42(2):101-106.   Published online June 30, 2010
DOI: https://doi.org/10.4143/crt.2010.42.2.101
AbstractAbstract PDFPubReaderePub
Purpose

The aim of this study was to determine whether the ERCC1 expression is effective to predict the clinical outcomes of patients with advanced gastric cancer (AGC) and who were treated with cisplatin-based first-line chemotherapy.

Materials and Methods

A total of 89 measurable AGC patients received cisplatin and capecitabine, with or without epirubicin, as a part of a randomized phase II study. Patients were included for the current molecular analysis if they had received two or more cycles of chemotherapy, their objective tumor responses were measured and if their paraffin-embedded tumor samples were available. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and the patients were divided into two groups (positive or negative) according to the presence of IHC staining of the tumor cell nuclei.

Results

Of the 32 eligible patients, 21 patients (66%) had tumor with a positive expression of ERCC1 and the remaining 11 patients had tumor with a negative ERCC1-expression. The ERCC1-negative patients achieved a higher response rate than that of the ERCC1-positive patients (44% vs. 28%, respectively), although the difference was not statistically significant (p=0.42). The median survival time for the all patients was 14.6 months (95% CI: 13.6 to 15.6 months). The one-year survival rate was similar for the ERCC1-negative patients (61%) and the ERCC1-positive patients (70%).

Conclusion

In the current study, the tumor ERCC1 expression by IHC staining could not predict the clinical response or survival of AGC patients who were treated with cisplatin-based first-line chemotherapy. The ERCC1 protein expression does not appear to be a useful tool for the selection of tailored chemotherapy for these patients.

Citations

Citations to this article as recorded by  
  • Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review
    Eduardo Henrique Cunha Neves Filho, Rosane Oliveira de Sant'Ana, Luiz Vianney Saldanha Cidrão Nunes, Adriana Pinheiro Bezerra Pires, Maria do Perpétuo Socorro Saldanha da Cunha
    APMIS.2017; 125(2): 79.     CrossRef
  • Predictive biomarkers for targeted and cytotoxic agents in gastric cancer for personalized medicine
    Shalong Wang, Lianwen Yuan
    BioScience Trends.2016; 10(3): 171.     CrossRef
  • Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy
    Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke, Jian-wei Bi
    Tumor Biology.2014; 35(4): 2941.     CrossRef
  • The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
    Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
    Tumor Biology.2014; 35(9): 8721.     CrossRef
  • Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
    Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
    Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107.     CrossRef
  • Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term
    Liqi Chen, Guoli Li, Jieshou Li, Chaogang Fan, Jian Xu, Bo Wu, Kun Liu, Caihua Zhang
    Cancer Chemotherapy and Pharmacology.2013; 71(4): 921.     CrossRef
  • ERCC1 C19007T polymorphism and the risk and invasiveness of cervical cancer in Korean women
    Seung‐Su HAN, Jae Weon KIM, Sang Hoon LEE, Dong Ho KIM, Noh‐Hyun PARK, Yong‐Sang SONG, Soon‐Beom KANG
    Asia-Pacific Journal of Clinical Oncology.2012;[Epub]     CrossRef
  • Gastric Cancer
    Joshua D. Lawson, Jason K. Sicklick, Paul T. Fanta
    Current Problems in Cancer.2011; 35(3): 97.     CrossRef
  • 10,123 View
  • 42 Download
  • 8 Crossref
Close layer
Increased ERCC Expression Correlates with Improved Outcome of Patients Treated with Cisplatin as an Adjuvant Therapy for Curatively Resected Gastric Cancer
Sun Kyung Baek, Si-Young Kim, Jae Jin Lee, Yoon Wha Kim, Hwi Joong Yoon, Kyung Sam Cho
Cancer Res Treat. 2006;38(1):19-24.   Published online February 28, 2006
DOI: https://doi.org/10.4143/crt.2006.38.1.19
AbstractAbstract PDFPubReaderePub
Purpose

It has been reported that the overexpression of the excision repair cross-complementing 1 (ERCC1) gene, which is essential for the repair of cisplatin (CDDP)-DNA adducts, negatively influences the effectiveness of CDDP-based therapy for primary gastric cancer. We investigated whether the ERCC1 expression was associated with survival for gastric cancer patients in an adjuvant setting.

Materials and Methods

We retrospectively analyzed 44 patients who were diagnosed with stage II or higher disease after undergoing curative resection and they had also received cisplatin-based chemotherapy. The ERCC1 expression was examined by performing immunohistochemical (IHC) staining, and this was divided into two groups according to the percentage of IHC staining of the tumor cell nuclei (negative: 10% or less, positive: more than 10%).

Results

Among the 44 patients (ERCC1-negative/ERCC1-positive group=16/28), 32 patients were male and their median age was 52 years. There was no difference for the baseline characteristics of the two groups. The median follow-up duration was 41 months. The median disease-free survival (DFS) and the overall survival (OS) for the ERCC1-positive group were significant higher than those of the ERCC1-negative group (DFS: 40.4 vs. 14.6 months, p=0.02, OS: undefined vs. 20.4 months, p=0.008).

Conclusion

The overall survival in gastric cancer patients who received cisplatin-based adjuvant chemotherapy after a curative resection is higher in those patients showing the overexpression of the ERCC1 gene. However, prospective studies using the ERCC1 gene expression as a prognostic marker for the DNA repair activity are needed.

Citations

Citations to this article as recorded by  
  • Somatic mutation of DNAH genes implicated higher chemotherapy response rate in gastric adenocarcinoma patients
    Chunchao Zhu, Qin Yang, Jia Xu, Wenyi Zhao, Zizhen Zhang, Danhua Xu, Yeqian Zhang, Enhao Zhao, Gang Zhao
    Journal of Translational Medicine.2019;[Epub]     CrossRef
  • The design, analysis and application of mouse clinical trials in oncology drug development
    Sheng Guo, Xiaoqian Jiang, Binchen Mao, Qi-Xiang Li
    BMC Cancer.2019;[Epub]     CrossRef
  • Methods and significance of the combined detection of HER2 gene amplification and chemosensitivity in gastric cancer
    Yang-Kun Wang, Su-Nan Wang, Ying-Ying Li, Gong-Ping Wang, Tian Yun, Chao-Ya Zhu, Bin-Feng Yang, Cong-Yang Li, Bo Jiang, Mei-Ling Zhu
    Cancer Biomarkers.2018; 21(2): 439.     CrossRef
  • The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy
    Jianning Song, Jie Yin, Zhigang Bai, Jun Zhang, Hua Meng, Jun Cai, Wei Deng, Xuemei Ma, Zhongtao Zhang
    Digestive Diseases and Sciences.2017; 62(5): 1223.     CrossRef
  • Haplotype analysis on relationship of ERCC2 and ERCC3 gene polymorphisms with osteosarcoma risk in Chinese young population
    Qiang Xu, Zuofu Zhang, Weixue Sun, Baiqiang Hu
    Mammalian Genome.2017; 28(5-6): 227.     CrossRef
  • Prognostic value of excision repair cross-complementation group 1 expression in gastric cancer: A meta-analysis
    PENG SONG, QIN YIN, MING LU, BO FU, BAOLIN WANG, QINGHONG ZHAO
    Experimental and Therapeutic Medicine.2015; 9(4): 1393.     CrossRef
  • Predictive value of excision repair cross-complementation group 1 expression for platinum-based chemotherapy and survival in gastric cancer: a meta-analysis
    Anqi Yao, You Wang, Xiaohong Peng, Rong Ye, Qiaoli Wang, Yuexiao Qi, Fuxiang Zhou
    Journal of Cancer Research and Clinical Oncology.2014; 140(12): 2107.     CrossRef
  • Association between epidermal growth factor receptor gene copy number and ERCC1, BRCA1 protein expression in Chinese patients with non-small cell lung cancer
    Yalei Zhang, Haihong Yang, Yuan Qiu, Qiuhua Deng, Jun Liu, Meiling Zhao, Ping He, Mingcong Mo, Xusen Zou, Jianxing He
    Medical Oncology.2014;[Epub]     CrossRef
  • The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis
    Kong-Kong Wei, Lei Jiang, Yao-Yao Wei, Yu-Feng Wang, Xuan-Kun Qian, Qiang Dai, Quan-Lin Guan
    Tumor Biology.2014; 35(9): 8721.     CrossRef
  • ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy
    Sara De Dosso, Elena Zanellato, Martina Nucifora, Renzo Boldorini, Angelica Sonzogni, Roberto Biffi, Nicola Fazio, Eraldo Bucci, Ottavio Beretta, Stefano Crippa, Piercarlo Saletti, Milo Frattini
    Cancer Chemotherapy and Pharmacology.2013; 72(1): 159.     CrossRef
  • Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma
    Malcolm H. Squires, Sarah B. Fisher, Kevin E. Fisher, Sameer H. Patel, David A. Kooby, Bassel F. El‐Rayes, Charles A. Staley, Alton B. Farris, Shishir K. Maithel
    Cancer.2013; 119(17): 3242.     CrossRef
  • GSTP1, ERCC1 and ERCC2 Polymorphisms, Expression and Clinical Outcome of Oxaliplatin-based Adjuvant Chemotherapy in Colorectal Cancer in Chinese Population
    Hui-Yan Li, Xin Ge, Guang-Ming Huang, Kai-Yu Li, Jing-Quan Zhao, Xi-Miao Yu, Wen-Si Bi, Yu-Lin Wang
    Asian Pacific Journal of Cancer Prevention.2012; 13(7): 3465.     CrossRef
  • Association of Four ERCC1 and ERCC2 SNPs with Survival of Bone Tumour Patients
    Ting Hao, Wei Feng, Jie Zhang, Yong-Jian Sun, Gang Wang
    Asian Pacific Journal of Cancer Prevention.2012; 13(8): 3821.     CrossRef
  • The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture
    Roderich E. Schwarz, John C. Mansour
    Annals of Surgical Oncology.2012; 19(7): 2081.     CrossRef
  • Clinicopathologic significance of ERCC1, thymidylate synthase and glutathione S-transferase P1 expression for advanced gastric cancer patients receiving adjuvant 5-FU and cisplatin chemotherapy
    Ki Han Kim, Hyuk-Chan Kwon, Sung Yong Oh, Sung Hyun Kim, Suee Lee, Kyung A Kwon, Jin Seok Jang, Min Chan Kim, Su-Jin Kim, Hyo-Jin Kim
    Biomarkers.2011; 16(1): 74.     CrossRef
  • ERCC1: Impact in Multimodality Treatment of Upper Gastrointestinal Cancer
    Ralf Metzger, Elfriede Bollschweiler, Arnulf H Hölscher, Ute Warnecke-Eberz
    Future Oncology.2010; 6(11): 1735.     CrossRef
  • Biomarker analysis in stage III–IV (M0) gastric cancer patients who received curative surgery followed by adjuvant 5-fluorouracil and cisplatin chemotherapy: epidermal growth factor receptor (EGFR) associated with favourable survival
    J-S Kim, M-A Kim, T M Kim, S-H Lee, D-W Kim, S-A Im, T-Y Kim, W H Kim, H-K Yang, D S Heo, Y-J Bang, K-U Lee, K-J Choe, N K Kim
    British Journal of Cancer.2009; 100(5): 732.     CrossRef
  • 12,789 View
  • 61 Download
  • 17 Crossref
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP